Late toxicity printout — Skin

Cited monitoring paradigm

Acute: ACS names field dermatitis, fatigue, hair loss in the field, and tenderness. Late: darker or more sensitive skin, texture change, field-skin counseling after chest RT, another skin cancer in or near the field, and lasting fatigue. Monitor: field infection during RT; new or changing lesions; lasting fatigue or sleep problems; a treatment summary. Those names are not encoded. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.

Not a fourth printout section. Cadences stay placeholders. Named tests are not encoded.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

ACS long-term and follow-up-care lists, named not encoded. Not a fourth printout section.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

ACS follow-up-care named contents. Not a fourth printout section.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS follow-up-care named steps. Not a fourth printout section.

Acute toxicities

During or shortly after RT. ACS early side effects.

• Radiation dermatitis — ACS names redness, irritation, swelling, blisters, itching, or peeling in the treated field.ACS-radiation-body
• Fatigue — ACS names fatigue as a common early RT side effect.ACS-radiation-body
• Hair loss in the field — ACS names hair thinning or loss only in the treated area.ACS-radiation-body
• Tenderness — ACS names a tender scalp or field after hair loss.ACS-radiation-body

Late toxicities

Months to years after RT. ACS delayed effects.

ACS long-term late names: Treatment summary for later problems

• Darker or more sensitive skin — ACS names treated skin that stays darker or more sensitive.ACS-radiation-body
• Texture change — ACS names thicker or firmer treated skin.ACS-radiation-body
• Field-skin counseling after chest RT — COG / ASCO-class radiation-field skin counseling stays a flag.COG-LTFU
• Another skin cancer in or near the field — ACS melanoma and BCC pages name a higher chance of another skin cancer. No invented NCCN month table.ACS-melanoma-follow
• Cancer-related fatigue that lasts — ACS long-term page names cancer-related fatigue as the most common long-term effect, lasting months or years and not always improving with rest. Sleep problems are also named and may have more than one cause.ACS-long-term-effects
• Joint or muscle pain after some treatments — ACS long-term page names joint or muscle pain after chemo, steroids, or hormone therapy. Symptoms may improve over time. People who are not physically active may have a higher risk. Not a rehab-interval engine.ACS-long-term-effects
• Mental health and distress after treatment — ACS long-term page names anxiety, depression, post-traumatic stress, loneliness, and fear of recurrence among common mental-health effects after cancer treatment. Not a mental-health screening engine.ACS-long-term-effects
• Treatment summary for later problems — ACS long-term page names a cancer treatment summary and survivorship care plan as the record of type, dose, and possible late effects. Those plans are not encoded.ACS-long-term-effects
• Second cancers after radiation or chemo — ACS adult second-cancers hub says a second cancer is a new unrelated cancer, not a recurrence. Radiation is linked to later AML, CML, ALL, or MDS, and to solid tumors that more often show up 10 years or more later, including breast, lung, thyroid, or bone and soft-tissue sarcomas. Chemo is linked most often to MDS and AML; ALL is also named. Chemo is named as a greater leukemia risk factor than radiation. Those names are not encoded. Complementary to the melanoma after-treatment page. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.ACS-second-cancers-adults
• Follow-up care plan after treatment — ACS follow-up-care page, developed with ASCO review, names a cancer treatment summary and a survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical, breast, colorectal, or lung screening may be named. Those plans and screens are not encoded. Complementary to the melanoma after-treatment page. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.ACS-follow-up-care

Named conditions to monitor

Red flags and suggested follow-up cadence placeholders. Not a personal calendar.

• Field infection or severe dermatitis

  Field infection or severe dermatitis — ACS says to tell the care team about skin changes so pain, irritation, and infection can be managed. On-treatment skin-care placeholder — not encoded.

  ACS-radiation-body

• New or changing lesion after melanoma or keratinocyte RT

  New or changing lesion after melanoma or keratinocyte RT — ACS names close follow-up because of recurrence and a new melanoma or other skin cancer. Keratinocyte stays labeled separately. Specialist-calendar placeholder. No invented NCCN month table.

  ACS-melanoma-follow

• Second-cancer testing after melanoma

  Second-cancer testing after melanoma — ACS says most experts do not recommend any other specific tests to look for second cancers unless there are symptoms. Symptom-directed placeholder — not a second-primary screening engine.

  ACS-melanoma-follow

• Ask for a treatment summary

  Ask for a treatment summary — ACS long-term page says to keep a treatment summary so later problems can be checked against the cancer history. Record-keeping placeholder — not encoded.

  ACS-long-term-effects

• Cancer-related fatigue or sleep problems that last

  Cancer-related fatigue or sleep problems that last — ACS long-term page names cancer-related fatigue as the most common long-term effect, plus sleep problems after treatment. Named months-or-years window is not encoded. Placeholder only — not a fatigue-score engine.

  ACS-long-term-effects

• Joint or muscle pain after chemo, steroids, or hormone therapy

  Joint or muscle pain after chemo, steroids, or hormone therapy — ACS long-term page names joint or muscle pain after those treatments and says symptoms may improve over time. Named activity and rehab steps are not encoded. Placeholder only — not a rehab-interval engine.

  ACS-long-term-effects

• Anxiety, depression, or fear of recurrence after treatment

  Anxiety, depression, or fear of recurrence after treatment — ACS long-term page names those as common types of mental distress among cancer survivors and says very worried, depressed, or angry feelings can affect daily life. Named support steps are not encoded. Placeholder only — not a mental-health screening engine.

  ACS-long-term-effects

• Second-cancer awareness after radiation or chemo

  Second-cancer awareness after radiation or chemo — ACS adult second-cancers hub names later MDS or leukemia after some chemo or radiation, and later solid tumors after radiation. Complementary to the melanoma after-treatment page. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine. Named several-year and 10-year windows are not encoded. Symptom-directed placeholder — not a second-primary screening engine.

  ACS-second-cancers-adults

• Ask which late-effect tests belong on the follow-up plan

  Ask which late-effect tests belong on the follow-up plan — ACS follow-up-care page names special tests after some treatments. Ask which tests belong on the plan. Those named tests are not encoded. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine. Named yearly and age-30 intervals are not encoded. Placeholder only — not a second-primary screening engine.

  ACS-follow-up-care